Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models

Fundamental and Clinical Pharmacology

Volumn 10, Issue 3, 1996, Pages 264-268

  Albengres, E ^a   Tillement, J P ^a   D'Athis, P ^b   Salducci, D ^c   Chauvet Monges, A M ^c   Crevat, A ^c  

^a FACULTÉ DE MÉDECINE   (France)

^b HÔPITAL DU BOCAGE   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cyclosporin A; Delayed hypersensitivity response; Lymphocyte proliferation; Trimetazidine

Indexed keywords

CD3 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ; TRIMETAZIDINE;

ADULT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029955326     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1996.tb00305.x     Document Type: Article

References (15)

1. Albengres E, Riant P, Morel M, et al. Onset and development of cyclosporin A effects on lymphocytes of cardiac patients before heart transplantation. Ther Drug Monit 1990;12:2-7
2. Anderson JE, Morris RE, Blaschke TE. Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Combined therapy potentiates cyclosporine immunosuppression and toxicity. Transplantation 1987;43:529-33
3. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the anti-ischemic agent trimetazidine. J Cardiovasc Pharmacol 1993;21:128-135
4. Chatenoud L, Baudrihaye MF, Kreis H. Human in vivo antigenic modulation induced by anti-T-cell OKT3 monoclonal antibody. Eur J Immunol 1982;12:979-982
5. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-288
6. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-958
7. Guamieri CH, Muscari C. Effect of trimetazidine on mitochondrial function and oxydative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993;46:324-331
8. Harpey C, Clauser P, Labrid C, Freyria JL, Poirier P. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989;6:292-312
9. Hess AD, Bright EC. Cyclosporine inhibits T-cell activation at two distinct levels : Role of the CD 28 activation pathways. Transplant Proc 1991;23:961-6
10. Hess AD, Tustchka PJ. Effects of cyclosporine A on human lymphocyte responses in vitro. I: CS allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immun 1980;24:2602-08
11. 31P-NMR Spectroscopy in the isolated Rat heart. Arch Int Pharmacodyn 1987;286:97-110
12. Nowell PC. Phytohaemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. Cancer Res 1960;20: 462-6
13. 31P-NMR spectroscopy study in the isolated rat heart. Cardiovasc Drugs Ther 1990;4:812-813
14. Weiss A, Imboden JB. T-cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987;41:1-4
15. White DJG, Plumb G, Pawelec G, Brons G. Cyclosporin A: an immunosuppressive agent preferentially against proliferative T cells. Transplantation 1979;27:55-58